CERS6 antisense RNA 1 (CERS6-AS1)

CERS6 antisense RNA 1 (CERS6-AS1) is a long non-coding RNA transcribed from the antisense strand at the CERS6 (Ceramide Synthase 6) gene locus. It has been identified as an oncogenic lncRNA in several cancers, including colorectal, breast, pancreatic, and colon cancer. CERS6-AS1 facilitates malignant phenotypes such as increased proliferation, migration, invasion, and stemness of tumor cells, while suppressing apoptosis[2][3][4][5][7]. Mechanistically, CERS6-AS1 primarily acts by serving as a competing endogenous RNA (ceRNA) that sequesters various tumor-suppressive microRNAs, including but not limited to miR-15b-5p, miR-16-5p, miR-217, and miR-6838-5p, thereby derepressing oncogenic targets such as SPTBN2, mitochondrial calcium uniporter, FGFR1, and YWHAG[3][4][5][7]. It is upregulated in tumor tissues and is associated with poor prognosis in patients. CERS6-AS1 is considered a potential therapeutic target and biomarker for multiple malignancies[2][5][7]. No current direct drug modulators of CERS6-AS1 are described in available literature.

Other names

CERS6-AS1Ceramide Synthase 6 Antisense RNA 1

Acts as a molecular sponge for microRNAs (e.g., miR-15b-5p, miR-16-5p, miR-6838-5p, miR-217, miR-15a-5p); Stabilizes mRNA of oncogenes or other targets (e.g., SPTBN2, mitochondrial calcium uniporter, FGFR1, YWHAG); Interacts with RNA-binding proteins (e.g., IGF2BP3, ELAVL1); Activates signaling pathways (e.g., RAF1/ERK pathway)